Clinical research jobs provider UCB has announced the latest set of results relating to its epilepsy medication Vimpat.
Data presented at the 65th Annual Meeting of the American Epilepsy Society in Baltimore this month stated there was a decrease in partial-onset seizure frequency among those who took the drug.
Dr William Rosenfeld, director of The Comprehensive Epilepsy Care Center for Children and Adults, St Louis, Missouri, explained how the results continued over a period of eight years.
He said: "Collectively, this body of evidence showed that lacosamide reduced seizure frequency and improved health-related quality of life."
Social functioning was one of the main areas those who took the anti-epileptic drug noted improvements in, while they were also less worried about the chances of experiencing seizures.
Earlier in the year, the clinical jobs provider revealed data collected from 12,718 patients showed the price of treating epilepsy patients with unstable epilepsy treatment is double the cost for stable patients over a two-year period.